## SUPPLEMENTAL MATERIALS

### Variable Activation of the DNA Damage Response Pathways in Patients Undergoing SPECT Myocardial Perfusion Imaging

Won Hee Lee, PhD<sup>1-3</sup>\*, Patricia Nguyen, MD<sup>1-4</sup>\*, Shijun Hu, PhD<sup>1,2</sup>, Grace Liang, BS<sup>3,4</sup>, Sang-Ging Ong, PhD<sup>1,2</sup>, Leng Han, PhD<sup>1,2</sup>, Veronica Sanchez-Freire, PhD<sup>2</sup>, Andrew S. Lee, PhD<sup>2</sup>, Minal Vasanawala, MD<sup>4</sup>, George Segall, MD<sup>4</sup>, Joseph C. Wu, MD, PhD<sup>1-3</sup>

<sup>1</sup>Department of Medicine, Division of Cardiology, <sup>2</sup>Department of Radiology, Molecular Imaging Program, <sup>3</sup>Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, <sup>4</sup>Veterans Administration Palo Alto, Palo Alto, CA

\*Contributed equally

#### SUPPLEMENTAL METHODS

#### In Vitro Irradiation and Culture

All irradiations were performed at room temperature. For measuring proteomic changes, we irradiated blood samples from healthy volunteers with a 800 Ci self-shielded <sup>137</sup>Cs  $\gamma$ -irradiator (J.L. Shepherd & Associates, San Fernando, CA) at an average dose rate of 1.38 Gy/min for low doses (e.g., 12.5, 25, or 50 mGy). Given that protein changes are short-lived but have been detected up to 5 hours after low dose radiation exposure,<sup>1</sup> we measured the changes in phosphorylation 2 hours after irradiation to assess the contribution of the initial SPECT dose on the overall phosphorylation. For gene expression analysis, we divided the total dose delivered (e.g., 25 mGy) into two fractions (1<sup>st</sup> irradiation: 25% of total dose versus 2<sup>nd</sup> irradiation: 75% of total dose 1.5 hours after 1<sup>st</sup> irradiation) in order to simulate doses administered to patients undergoing SPECT imaging. Control samples underwent sham irradiation. For incubation times longer than 30 minutes, blood samples were immediately diluted at a 1:1 ratio with RPMI 1640 medium (Mediatech Inc., Manassas, VA) containing 10% heat-inactivated fetal bovine serum after irradiation, returned to the CO<sub>2</sub> incubator, and maintained at 37°C in 5% CO<sub>2</sub>/95% air until the appropriate time point for analysis.

#### **Sample Preparation for T-lymphocyte Subpopulation**

Freshly isolated PBMCs were pre-incubated with 20 µl of FcR-blocking reagent (Miltenyi) and labeled by addition of CD3-Alexa Fluor 647 (BD Biosciences), CD4-phycoerythrin (PE; BD Biosciences), CD62L-phycoerythrin-cyanin7 (PECy7; eBioscience), CD45RA-allophycocyanin 780 (APC780; eBioscience), CD19-Alexa Fluor 700 (eBioscience), CD11-brilliant violet 605 (BioLegend, San Diego, CA) for 20 minutes on ice. Dead cells were excluded by adding 7-AAD

to the cell suspension prior to sorting. Using a FACS Aria (BD Biosciences), two subpopulations for CD3<sup>+</sup>CD4<sup>+</sup> and CD3<sup>+</sup>CD8<sup>+</sup> T-lymphocytes including naïve (CD62L<sup>+</sup>CD45RA<sup>+</sup>; Naïve) and central memory (CD62<sup>+</sup>CD45RA<sup>-</sup>; CM) were sorted directly into 96 well 0.2 ml PCR plates for single cell quantitative real-time PCR.

#### SUPPLEMENTAL FIGURE LEGENDS

Supplemental Figure 1. The percentage of phosphorylated cells for DNA damage-marker proteins in T-lymphocytes after exposure to low dose irradiation in vitro. T-lymphocytes were isolated 2 hours post-irradiation (0, 12.5, 25, or 50 mGy). (A) Total and phospho-H2AX ( $\gamma$ -H2AX), (B) phospho-p53, and (C) phospho-ATM were measured by flow cytometry (n=4-8). Two-dimensional dot plots of the percentage of total and phospho-H2AX detected at each radiation dose are shown in the upper left hand corner. The numbers in the upper right area of each dot plot reflect the percentage of cells that express each surface marker. The numbers in the upper left hand corner reflect those that express only yH2AX (phosphorylated H2AX). Those in the upper right hand corner are cells that express both yH2AX and H2AX. Those in the lower left hand corner are cells that express neither yH2AX nor H2AX (i.e., debris). Finally, those in the lower right hand corner are cells that express only H2AX. Line graphs showing the percentage of cells expressing phosphorylated DNA damage markers are shown in the remaining panels. Each individual data point represents a separate patient sample before (closed circle) and after in vitro low dose irradiation (open circle). Closed squares shown are displayed as mean  $\pm$  SEM for each group. \*Statistically significant from baseline (Bonferroni-adjusted P<0.05).

**Supplemental Figure 2.** The percentage of phosphorylated cells for DNA damage-marker proteins and relative mRNA expression of DNA repair-related genes in T-lymphocytes isolated from patients undergoing invasive X-ray angiography (**A**, **C**, and **E**) and echocardiography (**B**, **D**, and **F**). Total and phospho-H2AX ( $\gamma$ -H2AX), phospho-p53, and phospho-ATM at baseline, post-angiography (**A**), and post-echocardiography (**B**) were measured by flow cytometry (n=12 and n=9, respectively). Data shown are mean ± SEM for each group. \*Statistically significant

from baseline (Bonferroni-adjusted P<0.05). A scatter plot showing protein activation in individual patients post-angiography (**C**) and post-echocardiography (**D**) measured by flow cytometry. Relative mRNA expression levels of *Bax*, *Ddb2*, *Mdm2*, *Atf6*, *Tp53*, and *Bbc3* at 24 hours following diagnostic angiography (**E**) and at 24 hours or 48 hours following echocardiography (**F**) were determined by single cell quantitative real-time PCR (n=10 and n=11, respectively). Data shown are mean  $\pm$  SEM for each group. \*Statistically significant from baseline (Bonferroni-adjusted P<0.05).

**Supplemental Figure 3.** The relative mRNA expression level of selected DNA repair-related genes in T-lymphocytes after exposure to low dose irradiation *in vitro*. Whole blood samples were irradiated with either 0 or 25 mGy (e.g., delivered as divided doses). Samples were maintained for 0, 6, 24, and 48 hours post-irradiation and T-lymphocytes were then isolated. The relative mRNA expression levels of (A) *Bax*, (B) *Atf6*, (C) *Mdm2*, (D) *Polh*, (E) *Map4k4*, (F) *Ccng1*, (G) *Ddb2*, (H) *Tp53*, and (I) *Bbc3* in T-lymphocytes were determined by single cell quantitative real-time PCR. Data shown are mean  $\pm$  SEM for each group (n=3).

**Supplemental Figure 4.** Relative mRNA expression levels of (**A**) *Bax*, (**B**) *Ddb2*, (**C**) *Mdm2*, (**D**) *Atf6*, (**E**) *Tp53*, and (**F**) *Bbc3* in T-lymphocytes isolated from 27 patients at serial timepoints (i.e., baseline, 2 hours, 6 hours, 24 hours, and 48 hours) post-SPECT MPI were determined by single cell quantitative real-time PCR. Each individual data point at each time point represents a separate patient sample before (closed circle) and after SPECT MPI (open circle). Closed squares shown are displayed as mean  $\pm$  SEM for each group. The number of patients collected at each time point is indicated in the figure.

**Supplemental Figure 5.** Bar graphs depicting the percentage of patients with Down ( $\geq$  1.5-fold decrease), Up ( $\geq$  1.5-fold increase), and No change in mRNA gene expression levels of (**A**) *Bax*, (**B**) *Ddb2*, (**C**) *Mdm2*, (**D**) *Atf6*, (**E**) *Tp53*, and (**F**) *Bbc*3 at 24 and 48 hours post-SPECT MPI (n=49).

**Supplemental Figure 6.** Phosphorylated cells for DNA damage-marker proteins (**A-B**) and relative mRNA expression of DNA repair-related genes (**C-D**) in human T-lymphocytes collected from different age groups (young and middle aged) after exposure to *in vitro* fractionated low dose irradiation. Data shown are mean  $\pm$  SEM for each group (n=3).

**Supplemental Figure 7.** Relative mRNA expression of DNA repair-related genes in T-lymphocyte subpopulations after exposure to *in vitro* fractionated low dose irradiation (25 mGy). Relative mRNA expression levels of (**A**) *Bax*, (**B**) *Ddb2*, (**C**) *Mdm2*, (**D**) *Atf6*, (**E**) *Tp53*, and (**F**) *Bbc3* at 24 hours following irradiation were determined by single cell quantitative real-time PCR. Data shown are mean  $\pm$  SEM for each group (n=3). \*Statistically significant from baseline (Bonferroni-adjusted P<0.05).









BAX

A



D





ATF6

<u>MDM2</u>

















**Supplemental Figure 6** 



 $\mathbf{F}$ 





|                                  | Invasive X-ray<br>Angiography | Echocardiography |  |  |  |  |
|----------------------------------|-------------------------------|------------------|--|--|--|--|
| Age (years)                      | $63.7\pm13.8$                 | $65.7 \pm 17.3$  |  |  |  |  |
| Gender (%)                       |                               |                  |  |  |  |  |
| Male                             | 91.7                          | 93.3             |  |  |  |  |
| Female                           | 8.3                           | 6.7              |  |  |  |  |
| Race (%)                         |                               |                  |  |  |  |  |
| Caucasian                        | 75                            | 60               |  |  |  |  |
| Clinical Factors                 |                               |                  |  |  |  |  |
| Average BMI (kg/m <sup>2</sup> ) | $32.4\pm6.7$                  | $28.6\pm4.6$     |  |  |  |  |
| History of Smoking (%)           | 75                            | 73               |  |  |  |  |
| History of Cancer (%)            | 8.3                           | 13               |  |  |  |  |
| Total Radiation Dose             |                               |                  |  |  |  |  |
| Total DAP (cGy·cm <sup>2</sup> ) | 7418±5287                     | N/A              |  |  |  |  |
| Effective dose (mSv)             | 18.2±10.6                     | N/A              |  |  |  |  |

**Supplemental Table 1.** Demographic and clinical characteristics of patients undergoing X-ray angiography (n=12) and echocardiography (n=15).

Data presented as mean ± SD or percentages. BMI, body mass index; kg, kilogram; mSv, millisievert; DAP, dose area product.

**Supplemental Table 2.** Genes selected for *in vitro* and *in vivo* gene expression analysis by single cell quantitative real-time PCR.

| Gene Symbol | Description   | Function    |
|-------------|---|-------------|
| ATF6        | Activating transcription factor 6                     | Apoptosis   |
| BAX         | Bcl-2-associated X protein                            | Apoptosis   |
| BBC3        | BCL2 binding component 3                              | Apoptosis   |
| C12ORF5     | Chromosome 12 open reading frame 5                    | Cell cycle  |
| CCNG1       | Cyclin G1   | Cell cycle  |
| CDK4        | Cyclin-dependent kinase 4                             | Cell cycle  |
| CDKN1A      | Cyclin-dependent kinase inhibitor 1A                  | Cell cycle  |
| DCLRE1C     | DNA cross-link repair 1C                              | DNA repair  |
| DDB2        | Damage-specific DNA binding protein 2                 | DNA repair  |
| FDXR        | Ferredoxin reductase                                  | Apoptosis   |
| GADD45A     | Growth arrest and DNA-damage-inducible, alpha         | Cell cycle  |
| JUN         | Jun proto-oncogene                                    | Cell cycle  |
| MAP4K4      | Mitogen-activated protein kinase kinase kinase kinase | 4 Apoptosis |
| MDM2        | Mdm2 p53 binding protein homolog                      | Cell cycle  |
| PCNA        | Proliferating cell nuclear antigen                    | DNA repair  |
| POLH        | Polymerase (DNA directed), eta                        | DNA repair  |
| RAD 50      | RAD 50 homolog  | DNA repair  |
| SESN1       | Sestrin 1   | Cell cycle  |
| TP53 (P53)  | Tumor protein p53                                     | Apoptosis   |
| XPA         | Xeroderma pigmentosum, complementation group A        | DNA repair  |
| XPC         | Xeroderma pigmentosum, complementation group C        | DNA repair  |

**Supplemental Table 3.** Detection of DSBs in T-lymphocyte isolated from patients before and 30 minutes after SPECT by immunocytochemistry and flow cytometry (n=7).

|                   | Microscopy o<br>per | of the # of γH2AX f<br>T-lymphocyte | òci     | Flow cytometry of the % of γH2AX-positive<br>T-lymphocytes |                   |         |  |  |  |
|-------------------|---------------------|-------------------------------------|---------|--|-------------------|---------|--|--|--|
|                   | Baseline            | Post-SPECT                          | P value | Baseline   | Post-SPECT        | P value |  |  |  |
| Mean $\pm$ SE     | $1.13\pm0.05$       | $1.47\pm0.19$                       | 0.09    | $2.13\pm0.07$  | $2.31\pm0.18$     | 0.21    |  |  |  |
| Median (MAD, IQR) | 1.18 (0.10, 0.15)   | 1.38 (0.39, 0.68)                   |         | 2.17 (0.13, 0.12)  | 2.36 (0.34, 0.48) |         |  |  |  |
| MAD               | 0.10                | 0.39                                |         | 0.13   | 0.34              |         |  |  |  |
| IQR               | 0.15                | 0.68                                |         | 0.12   | 0.48              |         |  |  |  |

**Supplemental Table 4.** The relative mRNA expression of DNA repair-related genes in T-lymphocytes isolated from 27 patients at different time points post-SPECT categorized as down (down,  $\geq$ 1.5-fold decrease), up (up,  $\geq$ 1.5-fold increase), and no change (no $\Delta$ ).

| ID | BAX         |             |             |             | DDB2        |             |             | MDM2        |             |             | TP53        |             |             |             | BBC3        |             |             |             |             |             |
|----|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
|    | 2           | 6           | 24          | 48          | 2           | 6           | 24          | 48          | 2           | 6           | 24          | 48          | 2           | 6           | 24          | 48          | 2           | 6           | 24          | 48          |
| Α  | no $\Delta$ | n/a         | n/a         | no $\Delta$ | up          | n/a         | n/a         | up          | no $\Delta$ | n/a         | n/a         | no $\Delta$ | n/a         | n/a         | n/a         | n/a         | no $\Delta$ | n/a         | n/a         | no $\Delta$ |
| В  | down        | n/a         | down        | down        | down        | n/a         | down        | no $\Delta$ | down        | n/a         | down        | no $\Delta$ | no $\Delta$ | n/a         | no $\Delta$ | up          | no $\Delta$ | n/a         | no $\Delta$ | down        |
| С  | down        | no $\Delta$ | n/a         | n/a         | down        | no $\Delta$ | n/a         | n/a         | no $\Delta$ | no $\Delta$ | n/a         | n/a         | down        | no $\Delta$ | n/a         | n/a         | down        | no $\Delta$ | n/a         | n/a         |
| D  | no $\Delta$ | no $\Delta$ | n/a         | n/a         | no          | no $\Delta$ | n/a         | n/a         | no $\Delta$ | down        | n/a         | n/a         | no $\Delta$ | no $\Delta$ | n/a         | n/a         | no $\Delta$ | no $\Delta$ | n/a         | n/a         |
| Е  | no $\Delta$ | no $\Delta$ | no $\Delta$ | n/a         | down        | down        | down        | n/a         | down        | no $\Delta$ | no $\Delta$ | n/a         | up          | up          | down        | n/a         | no $\Delta$ | down        | down        | n/a         |
| F  | no $\Delta$ | down        | no $\Delta$ | n/a         | down        | down        | no $\Delta$ | n/a         | down        | down        | down        | n/a         | down        | no $\Delta$ | down        | n/a         | down        | no $\Delta$ | no $\Delta$ | n/a         |
| G  | no $\Delta$ | no $\Delta$ | no $\Delta$ | n/a         | no $\Delta$ | no $\Delta$ | no $\Delta$ | n/a         | no $\Delta$ | no $\Delta$ | no $\Delta$ | n/a         | no $\Delta$ | no $\Delta$ | no $\Delta$ | n/a         | down        | no $\Delta$ | n/a         | n/a         |
| Н  | down        | no $\Delta$ | down        | down        | no $\Delta$ | up          | down        | down        | up          | up          | down        | no $\Delta$ |
| I  | no $\Delta$ | no $\Delta$ | no $\Delta$ | no $\Delta$ | up          | up          | no $\Delta$ | up          | down        | up          | down        | no $\Delta$ | down        | no $\Delta$ | down        | no $\Delta$ | up          | no $\Delta$ | down        | no $\Delta$ |
| J  | no $\Delta$ | down        | no $\Delta$ | down        | no $\Delta$ | no $\Delta$ | down        | no $\Delta$ | no $\Delta$ | no $\Delta$ | down        | no $\Delta$ | up          | up          | no $\Delta$ | no $\Delta$ | up          | up          | up          | up          |
| K  | no $\Delta$ | down        | down        | down        | no $\Delta$ |
| L  | up          | no $\Delta$ | up          | up          | no $\Delta$ |
| М  | down        | no $\Delta$ | no $\Delta$ | up          | down        | down        | down        | no $\Delta$ | no $\Delta$ | no $\Delta$ | down        | no $\Delta$ | down        | down        | down        | down        |
| Ν  | no $\Delta$ | down        | no $\Delta$ | up          | no $\Delta$ | no $\Delta$ | up          | no $\Delta$ | no $\Delta$ | no $\Delta$ | up          | n/a         | n/a         | n/a         | n/a         |
| 0  | up          | up          | up          | up          | no $\Delta$ | no $\Delta$ | no $\Delta$ | up          | no $\Delta$ | up          | no $\Delta$ | up          | no $\Delta$ | no $\Delta$ | down        | up          | down        | down        | down        | no $\Delta$ |
| Р  | no $\Delta$ | no $\Delta$ | no $\Delta$ | up          | up          | up          | no $\Delta$ | up          | no $\Delta$ | no $\Delta$ | no $\Delta$ | up          | no $\Delta$ | no $\Delta$ | no $\Delta$ | up          | n/a         | n/a         | n/a         | n/a         |
| Q  | no $\Delta$ | no $\Delta$ | no $\Delta$ | up          | no $\Delta$ | down        | no $\Delta$ | no $\Delta$ | no $\Delta$ | no $\Delta$ | down        | no $\Delta$ | no $\Delta$ | no $\Delta$ | down        | no $\Delta$ | n/a         | n/a         | n/a         | n/a         |
| R  | no $\Delta$ | no $\Delta$ | no $\Delta$ | no $\Delta$ | down        | no $\Delta$ | down        | no $\Delta$ | down        | no $\Delta$ | no $\Delta$ | no $\Delta$ | down        | up          |
| S  | up          | no $\Delta$ | up          | n/a         | n/a         | n/a         | n/a         |
| Т  | no $\Delta$ | n/a         | down        | no $\Delta$ | no $\Delta$ | n/a         | no $\Delta$ | no $\Delta$ | no $\Delta$ | n/a         | down        | no $\Delta$ | down        | n/a         | no $\Delta$ | down        | n/a         | n/a         | n/a         | n/a         |
| U  | no $\Delta$ | n/a         | up          | down        | down        | n/a         | up          | down        | no $\Delta$ | n/a         | up          | down        | up          | n/a         | up          | no $\Delta$ | no $\Delta$ | n/a         | up          | no $\Delta$ |
| V  | down        | n/a         | up          | down        | down        | n/a         | up          | down        | no $\Delta$ | n/a         | no $\Delta$ | down        | down        | n/a         | no $\Delta$ | down        | down        | n/a         | no $\Delta$ | down        |
| W  | down        | n/a         | no $\Delta$ | down        | down        | n/a         | down        | no $\Delta$ | down        | n/a         | down        | down        | down        | n/a         | no $\Delta$ | down        | n/a         | n/a         | n/a         | n/a         |
| Х  | no $\Delta$ | n/a         | down        | down        | no $\Delta$ | n/a         | down        | down        | no $\Delta$ | n/a         | down        | down        | no $\Delta$ | n/a         | down        | down        | no $\Delta$ | n/a         | down        | down        |
| Y  | no $\Delta$ | n/a         | down        | down        | no $\Delta$ | n/a         | down        | down        | no $\Delta$ | n/a         | down        | no $\Delta$ | no $\Delta$ | n/a         | down        | down        | no $\Delta$ | n/a         | down        | down        |
| Z  | no $\Delta$ | n/a         | down        | down        | no $\Delta$ | n/a         | down        | down        | no $\Delta$ | n/a         | no $\Delta$ | no $\Delta$ | up          | n/a         | up          | n/a         | n/a         | n/a         | n/a         | n/a         |
| Z1 | no $\Delta$ | n/a         | no $\Delta$ | no $\Delta$ | no $\Delta$ | n/a         | no $\Delta$ | down        | no $\Delta$ | n/a         | no $\Delta$ | down        | down        | n/a         | no $\Delta$ | n/a         | n/a         | n/a         | n/a         | n/a         |

## SUPPLEMENTAL REFERENCES

1. Lobrich M, Rief N, Kuhne M, Heckmann M, Fleckenstein J, Rube C, Uder M. In vivo formation and repair of DNA double-strand breaks after computed tomography examinations. *Proc Natl Acad Sci U S A*. 2005;102:8984-8989.